Wobble Genomics: In the Spotlight
Stay informed with our latest updates, industry news, and publications.
Wobble Genomics: In the Spotlight
Stay informed with our latest updates, industry news, and publications.
Wobble Genomics: In the Spotlight
Stay informed with our latest updates, industry news, and publications.
January 1, 2023
StartUs Insights – 9 Computational Biology Trends in 2023
Share
Developments in high-performance computing and high-throughput hardware are advancing emerging computational biology trends. These trends are enabling novel drug development, nutrition analytics, and cancer therapies. Moreover, AI, machine learning, and high-performance computing allow large-volume data processing combining biological information from multiple sources for higher accuracy testing and modeling.
Innovation Map outlines the Top 9 Computational Biology Trends & 18 Promising Startups
For this in-depth research on the Top Computational Biology Trends & Startups, we analyzed a sample of 494 global startups & scaleups. The result of this research is data-driven innovation intelligence that improves strategic decision-making by giving you an overview of emerging technologies & startups in the computational biology industry. These insights are derived by working with our Big Data & Artificial Intelligence-powered StartUs Insights Discovery Platform, covering 2 500 000+ startups & scaleups globally. As the world’s largest resource for data on emerging companies, the SaaS platform enables you to identify relevant startups, emerging technologies & future industry trends quickly & exhaustively.
In the Innovation Map below, you get an overview of the Top 9 Computational Biology Trends & Innovations that impact 400+ companies worldwide. Moreover, the Computational Biology Innovation Map reveals 18 hand-picked startups, all working on emerging technologies that advance their field.
Top 9 Computational Biology Trends
- Genomics
- Drug Development
- Proteomics
- Biological Modeling
- Metabolomics
- Bioinformatics
- Transcriptomics
- Big Data
- Machine Learning
Genomics
Sequencing, mapping, and editing genomes play an important role in the development of a range of solutions across biotech, pharma, and life sciences. However, high computational time and costs limit the use of genomics. To overcome this, startups are developing genome sampling and analysis solutions that provide faster and better quality data for sequencing. Moreover, advances in genomics are enabling personalized treatment and care.
Reveal Genomics offers Gene Expression Analysis
Spanish startup Reveal Genomics develops diagnostic tools to determine therapeutic options for patients with cancer. Its genomic tool, HER2DX, identifies relapse risk, probability of therapy response, and tumor expression levels in early-stage HER2+ breast cancer. To do this, it measures and analyses the expression of 27 different genes. This allows clinicians to predict the benefits of targeted cancer therapies and reduce cancer recurrence.
Wobble Genomics advances Nucleic Acid Sequencing
UK-based startup Wobble Genomics advances nucleic acid sequencing for biomarker discovery. Its Level-Up library normalization technology increases sampling efficiency during sequencing. Moreover, it creates a uniform distribution of unique sequences in cDNA libraries, maximizing non-targeted sequencing efficiency. This way, the solution offers both increased sensitivity and accuracy.
Photo credit: StartUs Insights
Wobble Genomics, a biotechnology company focused on improving cancer outcomes through better diagnosis and therapy selection, presents new data at the 2025 San Antonio Breast Cancer Symposium (SABCS), (December 9-12), in San Antonio, Texas. The data demonstrates the ability to accurately detect HER2 expression in breast cancer, both in solid tumour biopsies and blood samples.
-
Edinburgh, UK, 6th May, 2025 – Wobble Genomics, a biotechnology company working to improve outcomes in cancer through better diagnosis and therapy selection, via a novel ultra-sensitive cell-free RNA (cfRNA) liquid biopsy diagnostic platform, today announced the appointment of Dr. Dietrich Stephan as Chairman of the Board. Dr. Stephan brings a track record in scaling
Wobble Genomics, a healthcare and biotechnology company at the forefront of long-read RNA sequencing, will today present new data at the San Antonio Breast Cancer Symposium (SABCS) that demonstrates the ability of its technology platform to provide deep biological insights critical for drug discovery and development, building on previous data which established the technology’s strong predictive performance as a diagnostic tool.
-
UK startup Wobble Genomics is eyeing the breast cancer early detection market with technology that enables it to capture rare and low-abundance RNA transcripts.
